MCK McKesson Corporation

XNYS Up Alert

Health Care

· How we analyze

About the company

McKesson is a US pharmaceutical wholesaler. The company distributes medicines to pharmacies and hospitals, supplies medical products to doctors’ offices and offers software and services for pharmacies and oncology practices. As of Oct 13, 2026

Fact sheet (from the annual report) Wholesale of drugs and drugstore products · Irving, USA

McKesson is a healthcare services company that works with pharmaceutical companies, healthcare providers, pharmacies, manufacturers and government agencies. The North American Pharmaceutical segment distributes branded drugs, generics, specialty drugs, biosimilars and over-the-counter products to pharmacies, hospitals and physicians in the United States and Canada. The Oncology & Multispecialty segment comprises specialty drug distribution and infusion services and supports a network of physician-led community oncology practices. Prescription Technology Solutions uses technology services such as electronic prior authorizations and price transparency to make it easier for patients to access affordable medicines. Another segment supplies consumables such as gloves, syringes and wound care to doctors’ offices, ambulatory surgery centers and post-acute care facilities and is to be separated.

Automatically summarized from SEC annual report (10-K, filed May 8, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −2.6%
  • 7 days −6.1%
  • 30 days +11.6%
  • 1 year +19.2%
Day range (last trading day)
0.0%Price at 2% of the range+2.7%
52-week range
−25.2%Price at 79% of the range+6.5%
Distance from the all-time high
−6.1%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Pullback in trend · Analysis method

This method currently detects no pattern for MCK. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:MCK

Fundamental analysis

McKesson Corporation · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of May 8, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Mar 31, 2026

Quality Profitability, consistency, balance sheet · 1 without data 2 of 7 criteria met Growth Revenue and earnings per share · 1 without data 6 of 6 criteria met Dividend Level, consistency, coverage 7 of 7 criteria met Financial strength Piotroski, debt, liquidity 2 of 6 criteria met

Quality 2 of 7 met · 1 without data

  • not met: Gross margin above 40% 3.6%
  • not met: Operating margin above 15% 1.5%
  • not met: Net margin above 10% 1.2%
  • no data: Return on equity above 15% negative equity
  • not met: Free cash flow margin above 10% 1.4%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% −2.6%
Gross margin

3.6% Fiscal year 2026

Rank 2 of 100: higher than 2% of 153 peers (All). weak.

Rank 3 of 100: higher than 3% of 20 peers (Sector). weak.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Operating margin

1.5% Fiscal year 2026

Rank 23 of 100: higher than 23% of 192 peers (All). weak.

Rank 23 of 100: higher than 23% of 20 peers (Sector). weak.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

1.2% Fiscal year 2026

Rank 18 of 100: higher than 18% of 237 peers (All). weak.

Rank 17 of 100: higher than 17% of 26 peers (Sector). weak.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on assets

5.8% Fiscal year 2026 (total assets at year end)

Rank 49 of 100: higher than 49% of 238 peers (All). medium.

Rank 44 of 100: higher than 44% of 26 peers (Sector). medium.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

−2.6% Fiscal year 2026

Rank 6 of 100: higher than 6% of 239 peers (All). weak.

Rank 13 of 100: higher than 13% of 26 peers (Sector). weak.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

1.4% Fiscal year 2026

Rank 21 of 100: higher than 21% of 213 peers (All). weak.

Rank 18 of 100: higher than 18% of 25 peers (Sector). weak.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

5.7B USD Fiscal year 2026

Operating cash flow minus capital expenditure on property and equipment.

Growth 6 of 6 met · 1 without data

  • met: Over 3 years, revenue grew by more than 5% per year +13.4%
  • met: Over 5 years, revenue grew by more than 5% per year +11.1%
  • met: Over 10 years, revenue grew by more than 5% per year +7.8%
  • met: Over 3 years, EPS grew by more than 5% per year +15.3%
  • no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +12.4%
Revenue growth 3 years

+13.4% per year

Rank 67 of 100: higher than 67% of 230 peers (All). strong.

Rank 82 of 100: higher than 82% of 25 peers (Sector). strong.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+11.1% per year

Rank 50 of 100: higher than 50% of 217 peers (All). medium.

Rank 62 of 100: higher than 62% of 25 peers (Sector). medium.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+7.8% per year

Rank 54 of 100: higher than 54% of 157 peers (All). medium.

Rank 24 of 100: higher than 24% of 19 peers (Sector). weak.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+15.3% per year

Rank 59 of 100: higher than 59% of 157 peers (All). medium.

Rank 80 of 100: higher than 80% of 22 peers (Sector). strong.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+14.7% per year

Rank 70 of 100: higher than 70% of 140 peers (All). strong.

Rank 73 of 100: higher than 73% of 20 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 3.17 USD
  • met: Payout ratio at most 60% of earnings 8%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +13.7%
  • met: Free cash flow per share covers the dividend 14.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 7% of free cash flow
Payout ratio

8% Fiscal year 2026

Dividend per share divided by earnings per share.

Dividend growth 5 years

+13.7% per year

Rank 72 of 100: higher than 72% of 118 peers (All). strong.

Rank 72 of 100: higher than 72% of 16 peers (Sector). strong.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

14.5x Fiscal year 2026

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 2 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 6 of 9
  • not met: Long-term debt no higher than equity negative equity
  • not met: Current assets cover current liabilities 0.85
  • not met: Positive equity −2.2B USD
  • met: In 5 years, share count up by at most 5% −22.7%
  • met: Free cash flow positive in the last fiscal year 5.7B USD
Piotroski F-Score

6 of 9 Fiscal year 2026

Rank 45 of 100: higher than 45% of 134 peers (All). medium.

Rank 32 of 100: higher than 32% of 19 peers (Sector). weak.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

negative equity at fiscal year end

No rank: too few peers or not computed yet.

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.85 at fiscal year end

Rank 13 of 100: higher than 13% of 215 peers (All). weak.

Rank 17 of 100: higher than 17% of 26 peers (Sector). weak.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−22.7% in 5 years

Rank 96 of 100: lower than 96% of 199 peers (All). strong.

Rank 90 of 100: lower than 90% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+11.1% per year), at least as fast as the sector median.
  • Light yellow: Net margin 1.2%, below the sector median (12.9%).
  • Light yellow: Profit in 9 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2017 (Apr 1, 2016 – Mar 31, 2017): Revenue 198.5B USD · Net income 5.1B USD · Net margin 2.6%
  2. Fiscal year 2018 (Apr 1, 2017 – Mar 31, 2018): Revenue 208.4B USD · Net income 67.0M USD · Net margin 0.0%
  3. Fiscal year 2019 (Apr 1, 2018 – Mar 31, 2019): Revenue 214.3B USD · Net income 34.0M USD · Net margin 0.0%
  4. Fiscal year 2020 (Apr 1, 2019 – Mar 31, 2020): Revenue 231.1B USD · Net income 900.0M USD · Net margin 0.4%
  5. Fiscal year 2021 (Apr 1, 2020 – Mar 31, 2021): Revenue 238.2B USD · Net income −4.5B USD · Net margin −1.9%
  6. Fiscal year 2022 (Apr 1, 2021 – Mar 31, 2022): Revenue 264.0B USD · Net income 1.1B USD · Net margin 0.4%
  7. Fiscal year 2023 (Apr 1, 2022 – Mar 31, 2023): Revenue 276.7B USD · Net income 3.6B USD · Net margin 1.3%
  8. Fiscal year 2024 (Apr 1, 2023 – Mar 31, 2024): Revenue 309.0B USD · Net income 3.0B USD · Net margin 1.0%
  9. Fiscal year 2025 (Apr 1, 2024 – Mar 31, 2025): Revenue 359.1B USD · Net income 3.3B USD · Net margin 0.9%
  10. Fiscal year 2026 (Apr 1, 2025 – Mar 31, 2026): Revenue 403.4B USD · Net income 4.8B USD · Net margin 1.2%

Fiscal year 2026 (Apr 1, 2025 – Mar 31, 2026): Revenue 403.4B USD · Net income 4.8B USD · Net margin 1.2%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2026

Of 100 USD of revenue, 3.6 USD gross profit, 1.5 USD operating income and 1.2 USD net income remained.

Money flow as a table
Fiscal year 2026, amounts in USD, share of revenue
ItemAmountof revenue
Revenue403.4B USD100.0%
Gross profit14.6B USD3.6%
Cost of revenue388.9B USD96.4%
Operating income6.2B USD1.5%
Operating expenses8.3B USD2.1%
Net income4.8B USD1.2%
Interest expense247.0M USD0.1%
Taxes1.1B USD0.3%
Other101.0M USD0.0%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from −2.1% to 1.5%.

Gross marginOperating marginNet margin
  1. Fiscal year 2017: Gross margin 5.7% · Operating margin 3.6% · Net margin 2.6%
  2. Fiscal year 2018: Gross margin 5.4% · Operating margin 0.4% · Net margin 0.0%
  3. Fiscal year 2019: Gross margin 5.5% · Operating margin 0.4% · Net margin 0.0%
  4. Fiscal year 2020: Gross margin 5.2% · Operating margin 1.1% · Net margin 0.4%
  5. Fiscal year 2021: Gross margin 5.1% · Operating margin −2.1% · Net margin −1.9%
  6. Fiscal year 2022: Gross margin 5.0% · Operating margin 0.8% · Net margin 0.4%
  7. Fiscal year 2023: Gross margin 4.5% · Operating margin 1.6% · Net margin 1.3%
  8. Fiscal year 2024: Gross margin 4.2% · Operating margin 1.3% · Net margin 1.0%
  9. Fiscal year 2025: Gross margin 3.7% · Operating margin 1.2% · Net margin 0.9%
  10. Fiscal year 2026: Gross margin 3.6% · Operating margin 1.5% · Net margin 1.2%

Returns

Return on equity fell in 3 years from 45.7% to 17.7%.

Return on equityReturn on assets
  1. Fiscal year 2017: Return on equity 45.7% · Return on assets 8.3%
  2. Fiscal year 2018: Return on equity 0.7% · Return on assets 0.1%
  3. Fiscal year 2019: Return on equity 0.4% · Return on assets 0.1%
  4. Fiscal year 2020: Return on equity 17.7% · Return on assets 1.5%
  5. Fiscal year 2021: Return on equity not available · Return on assets −7.0%
  6. Fiscal year 2022: Return on equity not available · Return on assets 1.8%
  7. Fiscal year 2023: Return on equity not available · Return on assets 5.7%
  8. Fiscal year 2024: Return on equity not available · Return on assets 4.5%
  9. Fiscal year 2025: Return on equity not available · Return on assets 4.4%
  10. Fiscal year 2026: Return on equity not available · Return on assets 5.8%

Equity and long-term debt

The equity ratio fell in 5 years from −0.0% to −2.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2017: Equity 11.1B USD · Long-term debt 8.4B USD
  2. Fiscal year 2018: Equity 9.8B USD · Long-term debt 7.9B USD
  3. Fiscal year 2019: Equity 8.1B USD · Long-term debt 7.6B USD
  4. Fiscal year 2020: Equity 5.1B USD · Long-term debt 7.4B USD
  5. Fiscal year 2021: Equity −21.0M USD · Long-term debt 7.1B USD
  6. Fiscal year 2022: Equity −2.3B USD · Long-term debt 5.9B USD
  7. Fiscal year 2023: Equity −1.9B USD · Long-term debt 5.6B USD
  8. Fiscal year 2024: Equity −2.0B USD · Long-term debt 5.6B USD
  9. Fiscal year 2025: Equity −2.1B USD · Long-term debt 5.7B USD
  10. Fiscal year 2026: Equity −2.2B USD · Long-term debt 6.5B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.03 to 0.85.

Current ratio
  1. Fiscal year 2017: Current ratio 1.04
  2. Fiscal year 2018: Current ratio 1.01
  3. Fiscal year 2019: Current ratio 1.02
  4. Fiscal year 2020: Current ratio 0.99
  5. Fiscal year 2021: Current ratio 1.03
  6. Fiscal year 2022: Current ratio 0.95
  7. Fiscal year 2023: Current ratio 0.92
  8. Fiscal year 2024: Current ratio 0.92
  9. Fiscal year 2025: Current ratio 0.90
  10. Fiscal year 2026: Current ratio 0.85

Cash flow

Free cash flow rose in 5 years from 4.1B USD to 5.7B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2017: Operating cash flow 4.7B USD · Capital expenditure 404.0M USD · Free cash flow 4.3B USD
  2. Fiscal year 2018: Operating cash flow 4.3B USD · Capital expenditure 405.0M USD · Free cash flow 3.9B USD
  3. Fiscal year 2019: Operating cash flow 4.0B USD · Capital expenditure 426.0M USD · Free cash flow 3.6B USD
  4. Fiscal year 2020: Operating cash flow 4.4B USD · Capital expenditure 362.0M USD · Free cash flow 4.0B USD
  5. Fiscal year 2021: Operating cash flow 4.5B USD · Capital expenditure 451.0M USD · Free cash flow 4.1B USD
  6. Fiscal year 2022: Operating cash flow 4.4B USD · Capital expenditure 388.0M USD · Free cash flow 4.0B USD
  7. Fiscal year 2023: Operating cash flow 5.2B USD · Capital expenditure 390.0M USD · Free cash flow 4.8B USD
  8. Fiscal year 2024: Operating cash flow 4.3B USD · Capital expenditure 431.0M USD · Free cash flow 3.9B USD
  9. Fiscal year 2025: Operating cash flow 6.1B USD · Capital expenditure 537.0M USD · Free cash flow 5.5B USD
  10. Fiscal year 2026: Operating cash flow 6.2B USD · Capital expenditure 436.0M USD · Free cash flow 5.7B USD

Share count

The share count fell in 5 years by 22.7% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2017: Diluted share count 223.0M
  2. Fiscal year 2018: Diluted share count 209.0M
  3. Fiscal year 2019: Diluted share count 197.0M
  4. Fiscal year 2020: Diluted share count 182.0M
  5. Fiscal year 2021: Diluted share count 160.6M
  6. Fiscal year 2022: Diluted share count 154.1M
  7. Fiscal year 2023: Diluted share count 142.2M
  8. Fiscal year 2024: Diluted share count 134.1M
  9. Fiscal year 2025: Diluted share count 128.1M
  10. Fiscal year 2026: Diluted share count 124.1M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.17 USD · Fiscal year 2026
Dividend growth per year
3 y +14.9%5 y +13.7%10 y +11.4%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 8% of free cash flow 7%
To shareholders (5 years)
19.7B USD 92% through repurchases
Share count over 5 years
−22.7% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 1.67 USD to 3.17 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2017: Dividend per share 1.12 USD
  2. Fiscal year 2018: Dividend per share 1.30 USD
  3. Fiscal year 2019: Dividend per share 1.51 USD
  4. Fiscal year 2020: Dividend per share 1.62 USD
  5. Fiscal year 2021: Dividend per share 1.67 USD
  6. Fiscal year 2022: Dividend per share 1.83 USD
  7. Fiscal year 2023: Dividend per share 2.09 USD
  8. Fiscal year 2024: Dividend per share 2.40 USD
  9. Fiscal year 2025: Dividend per share 2.75 USD
  10. Fiscal year 2026: Dividend per share 3.17 USD

Payout ratios

The payout ratio fell in 4 years from 25.3% to 8.3%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2017: Payout ratio (earnings) 4.9% · Payout ratio (free cash flow) 5.8%
  2. Fiscal year 2018: Payout ratio (earnings) 406.3% · Payout ratio (free cash flow) 6.6%
  3. Fiscal year 2019: Payout ratio (earnings) not available · Payout ratio (free cash flow) 8.1%
  4. Fiscal year 2020: Payout ratio (earnings) 32.7% · Payout ratio (free cash flow) 7.3%
  5. Fiscal year 2021: Payout ratio (earnings) not available · Payout ratio (free cash flow) 6.7%
  6. Fiscal year 2022: Payout ratio (earnings) 25.3% · Payout ratio (free cash flow) 6.8%
  7. Fiscal year 2023: Payout ratio (earnings) 8.3% · Payout ratio (free cash flow) 6.1%
  8. Fiscal year 2024: Payout ratio (earnings) 10.7% · Payout ratio (free cash flow) 8.1%
  9. Fiscal year 2025: Payout ratio (earnings) 10.7% · Payout ratio (free cash flow) 6.2%
  10. Fiscal year 2026: Payout ratio (earnings) 8.3% · Payout ratio (free cash flow) 6.7%

What goes back to shareholders

Over 5 years, 19.7B USD went back to shareholders, 92% of it through share repurchases. That is 82% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2017: Dividends paid 253.0M USD · Share repurchases 2.3B USD · New shares issued (including employee plans) not available · Free cash flow 4.3B USD
  2. Fiscal year 2018: Dividends paid 262.0M USD · Share repurchases 1.7B USD · New shares issued (including employee plans) not available · Free cash flow 3.9B USD
  3. Fiscal year 2019: Dividends paid 292.0M USD · Share repurchases 1.6B USD · New shares issued (including employee plans) not available · Free cash flow 3.6B USD
  4. Fiscal year 2020: Dividends paid 294.0M USD · Share repurchases 2.0B USD · New shares issued (including employee plans) not available · Free cash flow 4.0B USD
  5. Fiscal year 2021: Dividends paid 276.0M USD · Share repurchases 770.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.1B USD
  6. Fiscal year 2022: Dividends paid 277.0M USD · Share repurchases 3.5B USD · New shares issued (including employee plans) not available · Free cash flow 4.0B USD
  7. Fiscal year 2023: Dividends paid 292.0M USD · Share repurchases 3.6B USD · New shares issued (including employee plans) not available · Free cash flow 4.8B USD
  8. Fiscal year 2024: Dividends paid 314.0M USD · Share repurchases 3.0B USD · New shares issued (including employee plans) not available · Free cash flow 3.9B USD
  9. Fiscal year 2025: Dividends paid 345.0M USD · Share repurchases 3.1B USD · New shares issued (including employee plans) not available · Free cash flow 5.5B USD
  10. Fiscal year 2026: Dividends paid 381.0M USD · Share repurchases 4.8B USD · New shares issued (including employee plans) not available · Free cash flow 5.7B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

McKesson Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MCK, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation this stock 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health 402.1B USD +8.4%45.0%1.2%0.4%2.4%29.7%1.9%7/9
CI Cigna 274.9B USD +11.4%21.8%3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+11.1% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 11.1% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

1.2% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 1.18 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was −1.9%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: negative equity

– latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

8% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.08 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
403.4B USD
Revenue vs. prior year
+12.4%
Net income (FY)
4.8B USD
Net income vs. prior year
+44.5%
EPS (FY)
38.38 USD
13F funds with a position
2 of 9
Funds vs. prior quarter
+1
Shares held vs. prior quarter
+1,095.1%
Fiscal year to Mar 31, 2026 · 10-K filed May 8, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2026Mar 31, 2026 403.4B4.8B 1.2% 38.38 3.17 8%
2025Mar 31, 2025 359.1B3.3B 0.9% 25.72 2.75 11%
2024Mar 31, 2024 309.0B3.0B 1.0% 22.39 2.40 11%
2023Mar 31, 2023 276.7B3.6B 1.3% 25.03 2.09 8%
2022Mar 31, 2022 264.0B1.1B 0.4% 7.23 1.83 25%
2021Mar 31, 2021 238.2B−4.5B −1.9% −28.26 1.67 –
2020Mar 31, 2020 231.1B900.0M 0.4% 4.95 1.62 33%
2019Mar 31, 2019 214.3B34.0M 0.0% 0.17 1.51 888%
2018Mar 31, 2018 208.4B67.0M 0.0% 0.32 1.30 406%
2017Mar 31, 2017 198.5B5.1B 2.6% 22.73 1.12 5%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 105.4B614.0M 0.6% 5.15 0.82 16%
Q1/26*Mar 31, 2026 96.3B1.7B 1.7% – 0.82 –
Q4/25Dec 31, 2025 106.2B1.2B 1.1% 9.59 0.82 9%
Q3/25Sep 30, 2025 103.2B1.1B 1.1% 8.92 0.82 9%
Q2/25Jun 30, 2025 97.8B784.0M 0.8% 6.25 0.71 11%
Q1/25*Mar 31, 2025 90.8B1.3B 1.4% – 0.71 –
Q4/24Dec 31, 2024 95.3B879.0M 0.9% 6.95 0.71 10%
Q3/24Sep 30, 2024 93.7B241.0M 0.3% 1.87 0.71 38%
Q2/24Jun 30, 2024 79.3B915.0M 1.2% 7.00 0.62 9%
Q1/24*Mar 31, 2024 76.4B791.0M 1.0% – 0.62 –
Q4/23Dec 31, 2023 80.9B589.0M 0.7% 4.42 0.62 14%
Q3/23Sep 30, 2023 77.2B664.0M 0.9% 4.92 0.62 13%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $1.2M3 people −$1.2M
6 months $00 people $24.8M7 people −$24.8M
12 months $00 people $29.1M8 people −$29.1M

Latest transactions

  • Oct 15, 2026 Fraga Francisco Officer Open-market sale · 10b5-1 plan 800 shares · $797.1K · SEC
  • Sep 8, 2026 Rutledge Napoleon B JR Officer Open-market sale · 10b5-1 plan 111 shares · $99.0K · SEC
  • Aug 10, 2026 Lerman Bradley E Director Open-market sale 301 shares · $268.6K · SEC
  • Jul 7, 2026 Tyler Brian S. Chief executive (CEO), Director Open-market sale · 10b5-1 plan 8,463 shares · $6.7M · SEC
  • Jun 17, 2026 Tyler Brian S. Chief executive (CEO), Director Open-market sale · 10b5-1 plan 8,463 shares · $6.6M · SEC
  • Jun 9, 2026 Tyler Brian S. Chief executive (CEO), Director Open-market sale · 10b5-1 plan 4,929 shares · $3.8M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +70

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows-10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)29.6
Rel. strength 60 d+15.7%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MCK yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MCK

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close